Rosiglitazone and Insulin Resistance in Renally Impaired Patients
Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
30 non-diabetic, non-obese patients with stage 4 chronic kidney disease will be asked to
participate in this metabolic study.
The primary aim of this study is to determine the effect of rosiglitazone on insulin
resistance in non-obese patients with non-diabetic stage 4 CKD.
Secondary end points are the effects on inflammation (hsCRP), lipid profile, bone density and
body composition.